Pharmerging Markets 2012-2016

Pharmerging Markets 2012-2016

Category : Pharmaceuticals

------------ Or -------------

TechNavio's analysts forecast the Pharmerging market to grow at a CAGR of 12.44 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increase in healthcare spending. The Pharmerging market has also been witnessing an increase in partnerships among vendors. However, the price pressure could pose a challenge to the growth of this market. 
TechNavio's report, the Pharmerging Market 2012-2016, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the pharmerging regions, namely: China, Brazil, Russia, India, Mexico, Turkey, Poland, Indonesia, Argentina, Egypt, Pakistan, South Africa, Thailand, Romania, Ukraine, Venezuela, and Vietnam; it also covers the Pharmerging market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
The key vendors dominating this market space are Abbott Laboratories, Amgen Inc., Astellas Pharma Inc., AstraZeneca plc., Bayer HealthCare AG., Boehringer Ingelheim Pharmaceuticals Corp. Bristol-Myers Squibb Co., Eisai Co Ltd., GlaxoSmithKline plc, Johnson & Johnson, Eli Lilly and Co., Merck & Co Inc. Novartis International AG., Novo Nordisk A/S., Pfizer Inc., Roche Holding Ltd., and Sanofi S.A.
Key questions answered in this report: 
What will the market size be in 2016 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.



01. Executive Summary

02. Scope of the Report

02.1 Market Overview

03. Market Research Methodology

03.1 Market Research Process

03.2 Research Design

03.3 Research Methodology

04. List of Abbreviations

05. Introduction

06. Market Landscape

06.1 Market Overview

06.2 Global Pharmaceutical Market

06.2.1 Market Size and Forecast

06.2.2 Global Pharmaceutical Market Vs Pharmerging Markets

06.3 Pharmerging Markets

06.3.1 Market Size and Forecast

06.3.2 Market Share of Pharmerging Markets vs Global Pharmaceutical Market

06.3.3 Pharmaceutical Spending in Pharmerging Markets

06.4 Five Forces Analysis

07. Market Segmentation by Geographical Regions

07.1 Pharmerging Markets Segmentation by Countries 2012-2016

07.2 SnapShot of Phamerging Markets

07.2.1 Pharmerging Markets Share by Country

08. Market Overview of Tier 1 Countries

08.1 Pharmaceutical Market in China

08.1.1 Market Size and Forecast

09. Market Overview of Tier 2 Countries

09.1 Pharmaceutical Market in Brazil

09.1.1 Market Size and Forecast

09.2 Pharmaceutical Market in Russia

09.2.1 Market Size and Forecast

09.3 Pharmaceutical Market in India

09.3.1 Market Size and Forecast

10. Tier 3 Countries

10.1 Pharmaceutical Market in Mexico

10.1.1 Market Size and Forecast

10.2 Pharmaceutical Market in Turkey

10.2.1 Market Size and Forecast

10.3 Pharmaceutical Market in Poland

10.3.1 Market Size and Forecast

10.4 Pharmaceutical Market in Indonesia

10.4.1 Market Size and Forecast

10.5 Pharmaceutical Market in Other Pharmerging Regions

10.5.1 Market Size and Forecast

11. Buying Criteria

12. Market Growth Drivers

13. Drivers and their Impact

14. Market Challenges

15. Impact of Drivers and Challenges

16. Market Trends

17. Trends and their Impact

18. Vendor Landscape

18.1 Competitive Scenario

18.1.1 Key News

18.1.2 Mergers and Acquisitions

18.2 Top Pharmaceutical Companies in Pharmerging Markets

19. Key Vendor Analysis

19.1 Pfizer Inc

19.1.1 Business Overview

19.1.2 Business Segmentation

19.1.3 Key Information

19.1.4 SWOT Analysis

19.2 Novartis AG

19.2.1 Business Overview

19.2.2 Business Segmentation

19.2.3 Key Information

19.2.4 SWOT Analysis

19.3 Johnson &Johnson

19.3.1 Business Overview

19.3.2 Business Segmentation

19.3.3 Key Information

19.3.4 SWOT Analysis

19.4 Merck & Co. Inc.

19.4.1 Business Overview

19.4.2 Business Segmentation

19.4.3 Key Information

19.4.4 SWOT Analysis

19.5 GlaxoSmithKline plc

19.5.1 Business Overview

19.5.2 Business Segmentation

19.5.3 Key Information

19.5.4 SWOT Analysis

19.6 Eli Lilly and Co.

19.6.1 Business Overview

19.6.2 Business Segmentation

19.6.3 Key Information

19.6.4 SWOT Analysis

20. Other Reports in this Series

List of Exhibits

Exhibit 1: Market Research Methodology

Exhibit 2: Global Pharmaceutical Market 2012-2016 (US $billion)

Exhibit 3: Global Pharmaceutical Market 2012 (in percent)

Exhibit 4: Pharmerging Markets 2012-2016 (US$ billion)

Exhibit 5: Pharmerging Markets Share 2012-2016 (in percent)

Exhibit 6: Pharmaceutical Spending in Pharmerging markets 2012-2016 (US$ billion)

Exhibit 7: Pharmaceutical Spending in Pharmerging Markets forecast 2012-2016  (US$ billion)

Exhibit 8: Pharmerging Markets Segmentation by Countries

Exhibit 9: Pharmerging Markets Share 2012-2016 (in percent)

Exhibit 10: Pharmerging Markets Share by Country  2012

Exhibit 11: Geographic Representation of Tier 1 Countries

Exhibit 12: Pharmaceutical Market in China  2012-2016 (US$ billion)

Exhibit 13: Geographic Representation of Tier 2 Countries

Exhibit 14: Pharmaceutical Market in Brazil 2012-2016 (US$ billion)

Exhibit 15: Pharmaceutical Market in Russia 2012-2016 (US$ billion)

Exhibit 16: Pharmaceutical Market in India 2012-2016 (US$ billion)

Exhibit 17: Geographic Representation of Tier 3 Countries

Exhibit 18: Pharmaceutical Market in Mexico 2012-2016 (US$ billion)

Exhibit 19: Pharmaceutical market in Turkey 2012-2016 (US$ billion)

Exhibit 20: Pharmaceutical Market in Poland 2012-2016 (US$ billion)

Exhibit 21: Pharmaceutical Market in Indonesia 2012-2016 (US$ billion)

Exhibit 22: Pharmaceutical Market in Other Pharmerging Regions 2012-2016 (US$ billion)

Exhibit 23: Pharmerging Markets Share Forecast in Revenue by Country 2012-2016 (US$ billion)

Exhibit 24: Pharmerging Markets Share Forecast by Country  2012-2016 (in percent)

Exhibit 25: Business Segmentation of Pfizer Inc.

Exhibit 26: Business Segmentation of Novartis  AG

Exhibit 27: Business Segmentation of Johnson& Johnson

Exhibit 28: Business Segmentation of Merck& Co. Inc.

Exhibit 29: Business Segmentation of GlaxoSmithKline plc

Exhibit 30: Business Segmentation of Eli Lilly and Co.

Enquiry Before Buy